Legend Biotech Corporation (FRA:9LB)
29.80
+8.20 (37.96%)
Last updated: Jun 3, 2026, 5:00 PM CET
Legend Biotech Revenue
Legend Biotech had revenue of $305.10M USD in the quarter ending March 31, 2026, with 56.46% growth. This brings the company's revenue in the last twelve months to $1.14B, up 56.38% year-over-year. In the year 2025, Legend Biotech had annual revenue of $1.03B with 64.02% growth.
Revenue (ttm)
$1.14B
Revenue Growth
+56.38%
P/S Ratio
5.86
Revenue / Employee
$367.35K
Employees
3,100
Market Cap
5.79B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03B | 401.60M | 64.02% |
| Dec 31, 2024 | 627.30M | 342.20M | 120.03% |
| Dec 31, 2023 | 285.10M | 168.10M | 143.66% |
| Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
| Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
| Dec 31, 2020 | 75.00M | 15.02M | 25.04% |
| Dec 31, 2019 | 59.98M | 10.85M | 22.08% |
| Dec 31, 2018 | 49.13M | 25.54M | 108.24% |
| Dec 31, 2017 | 23.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 635.20M |
| Darwin AG | 54.30M |
| Paion AG | 14.81M |
| 2invest AG | 8.89M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 57.01K |
| co.don AG | 22.00K |
| bioXXmed AG | 20.49K |
Legend Biotech News
- 7 hours ago - Legend Biotech price target raised to $49 from $31 at UBS - TheFly
- 8 hours ago - Legend Biotech price target raised to $65 from $50 at H.C. Wainwright - TheFly
- 1 day ago - This Is Why Legend Biotech Stock (LEGN) Was Up Today - TipRanks
- 1 day ago - Legend Biotech rises 29.5% - TheFly
- 1 day ago - Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress - TheFly
- 1 day ago - Legend's experimental cell therapy shows promise in blood cancer patients - Reuters
- 1 day ago - Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - GlobeNewsWire
- 2 days ago - Legend Biotech presents first-in-human LB2102 results in solid tumors - TheFly